ABT-436
As of the edition of 20 October 2026, ABT-436 is a drug known only by a code name: stopped in 2015; acts on AVPR1B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2015
- Kind
- Code name only
- Registered trials
- 3, 1 stopped early
- Disease areas
- Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of ABT-436.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AVPR1B | Vasopressin V1b receptor | P47901 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 3 |